Titan Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for a Phase 1 study of its six-month or longer subdermal formulation of nalmefene, an opioid antagonist, intended for the prevention of relapse following opioid detoxification in adults with Opioid Use Disorder.